Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.

@article{Kielstein1999AsymmetricDP,
  title={Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.},
  author={Jan T Kielstein and Rainer H. B{\"o}ger and Stefanie Margarethe Bode-B{\"o}ger and Juergen Schaeffer and M M Barbey and Karl Koch and J{\"u}rgen C. Fr{\"o}lich},
  journal={Journal of the American Society of Nephrology : JASN},
  year={1999},
  volume={10 3},
  pages={594-600}
}
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide (NO) synthase. Its concentration is elevated in patients with end-stage renal disease (ESRD), in part because it is excreted via the kidneys. In this study, the plasma concentrations of ADMA, symmetric dimethylarginine, and L-arginine were determined in relation to… CONTINUE READING